<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="(L), and non-structural proteins such as sGP (3-6). Efficient viral" exact="infection" post="requires at least two cellular receptors, the endo/lysosomal cholesterol"/>
 <result pre="(10). Since 1976 when this virus was first identified, its" exact="infection" post="has caused Ebola hemorrhagic fever (EHF) in humans with"/>
 <result pre="is imperative to develop prophylactic or therapeutic antivirals against EBOV" exact="infection" post="(12). Several high-throughput screening (HTS) methods, including monocistronic minigenome"/>
 <result pre="prophylactic or therapeutic antivirals against EBOV infection (12). Several high-throughput" exact="screening" post="(HTS) methods, including monocistronic minigenome technology and pseudotyped viral"/>
 <result pre="compounds against EBOV (13-16). These strategies facilitated safe and robust" exact="screening" post="of antivirals in biosafety level 2 (BSL2) facilities without"/>
 <result pre="infected cells with the trVLP system derived from EBOV. After" exact="treatment" post="of 2,354 small organic compounds, we measured their effects"/>
 <result pre="were higher than 0.5, which suggested the reliability of the" exact="screening" post="assay. We primarily selected 86 hits with relative RLuc"/>
 <result pre="15 anti-EBOV compounds with selectivity indices higher than 10 by" exact="screening" post="a chemical library of compounds tested for clinical trials."/>
 <result pre="using SsoFast EvaGreen Supermix (Bio-Rad) and the CFX96 real-time PCR" exact="detection" post="system (Bio-Rad). To calculate the relative fold changes, the"/>
 <result pre="of approved drugsEmerg Microbes Infect3e8410.1038/emi.2014.8826038505 15WangYCuiRLiGet al.2016Teicoplanin inhibits Ebola pseudovirus" exact="infection" post="in cell cultureAntiviral Res1251710.1016/j.antiviral.2015.11.00326585243 16WelchSRGuerreroLWChakrabartiAKet al.2016Lassa and Ebola virus"/>
 <result pre="software for automatically calculating drug inhibitory concentrations from in vitro" exact="screening" post="assaysPLoS One9e10618610.1371/journal.pone.010618625184280 19LeeNShumDKonigAet al.2018High-throughput drug screening using the Ebola"/>
 <result pre="concentrations from in vitro screening assaysPLoS One9e10618610.1371/journal.pone.010618625184280 19LeeNShumDKonigAet al.2018High-throughput drug" exact="screening" post="using the Ebola virus transcription- and replication-competent virus-like particle"/>
 <result pre="human rhinovirusACS Med Chem Lett966767210.1021/acsmedchemlett.8b0013430034598 27JangYShinJSYoonYSet al.2018Salinomycin inhibits influenza virus" exact="infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
 <result pre="acidification and viral matrix protein 2 functionJ Virol92e014411810.1128/JVI.01441-1830282713 28SvenssonJLonnLJanssonJOet al.1998Two-month" exact="treatment" post="of obese subjects with the oral growth hormone (GH)"/>
 <result pre="compounds using the trVLP system. (A) Flow chart showing the" exact="screening" post="procedure. (B) Z’ factor plot derived from HTS performed"/>
 <result pre="NP (middle), or β-actin (lower). -V, no transfection and no" exact="infection" post="control. M, trVLP-infected, DMSO-treated mock control. (B) Confocal microscopy"/>
 <result pre="control. M, trVLP-infected, DMSO-treated mock control. (B) Confocal microscopy for" exact="detection" post="of viral GP. HEK293T cells were transfected and infected"/>
</results>
